News

Lilly stock falls as Mounjaro fails to show superiority over Trulicity
Eli Lilly and Company (NYSE:LLY) stock fell on Thursday morning after the pharmaceutical giant’s diabetes drug Mounjaro ...
BioSpace2h
Lilly’s Mounjaro ‘Good Enough’ in Cardio Trial, Will Seek Expanded Approval
While Eli Lilly’s diabetes blockbuster was non-inferior to its older incretin therapy Trulicity in a highly anticipated Phase III cardiovascular outcomes trial, analysts had hoped for statistical ...
Eli Lilly Obesity Drug Mounjaro Beats Legacy Trulicity On Cardio-Renal Health
Eli Lilly's Mounjaro matched Trulicity in heart outcomes and showed added benefits on A1C, weight, kidney function, and ...
Fierce Pharma5h
Lilly's Mounjaro shows its cardio benefits in Trulicity head-to-head trial
A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label ...
Devdiscourse2h
Mounjaro Overshadows Trulicity in Life-Saving Diabetes Battle
Eli Lilly's Mounjaro diabetes drug has demonstrated superior performance over Trulicity in reducing heart attack and stroke ...
Eli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.
A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...
Eli Lilly's Mounjaro met goal of cardiovascular benefit in head-to-head trial with Trulicity
CNBC's Angelica Peebles joins 'Squawk Box' with the latest news from Eli Lilly. Mom Worried If New Rescue Dog Had ‘Bonded’ ...
Eli Lilly (LLY) Gets Price Target Boost as Analysts See Strong Mounjaro, Zepbound Sales
Eli Lilly & Company (NYSE:LLY) ranks among the best low volatility stocks to buy according to analysts. On July 11, ...